The only shingles vaccine to achieve ≥90% efficacy across all age groups studied
Lately, Biotech and immunotherapy have been widely covered by media, but there’s more to healthcare than taking leaps of faith on new tech. New companies are addressing administrative functions, personalized medicine, and proactive wellness in their approach to the health industry.
Several Mobile-Health companies are joining hands to create a clinician-facing platform for assuring data quality and patient identification in remote patient monitoring programs.
Flatiron announced a three-year agreement with Bristol-Myers Squibb (BMS) a leading pharma company from the US. BMS is planning to use Flatiron’s expertise to expand real-world evidence to develop Bristol’s experimental cancer drugs.
Recode project will use Cellectis’ TALEN gene editing technology to create first virus-resistant human cells for manufacturing therapeutics and developing new cell-based therapies
In the first quarter of 2018, Swiss pharmaceuticals and diagnostics player Roche group’s sales rose by 6% to CHF 13.6 billion. Sales in the pharma division increased by 7% CHF 10.7 billion mainly by strong growth in Ocrevus and Perjeta.
The University Of Kansas Medical Center is partnering with Garmin Health to foster innovation and better understand on how healthcare wearables can help in the detection and management of significant medical conditions. Their first research will focus on cardiac care and sleep apnea.
California-based Casetabs, the pioneer of cloud-based surgery coordination technology, yesterday announced it has received $6 million in series A-funding to scale its surgery coordination application.
US patient-centric data analytics company, Trayt Technologies (formerly Ava Health), has developed an app to help improve the diagnosis, treatment, and quality of life for patients with autism, ADHD and other neurodevelopmental and brain disorders.
Based on data from the phase II JULIET study, tisagenlecleucel (Kymriah) has received FDA approval for the treatment of adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma—after 2 or more lines of systemic therapy.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.